

Global use of GPHF-Minilabs for the detection of falsified and substandard medicines

Africa	
Benin	1
Cape Verde	1
Central African Republic	1
Chad	1
Djibouti	1
Niger	1
Swaziland	1
Botswana	2
Congo PR	2
Gambia	2
Guinea-Equatorial	2
Ivory Coast	2
Lesotho	2
Mauritania	2
Namibia	2
Burkina Faso	3
Guinea-Bissau	3
Sudan	3
Togo	3
Eritrea	4
Gabun	4
Zimbabwe	4
South Sudan	5
Guinea-Conakry	6


Asia	
Somalia	6
Malawi	7
Liberia	8
Burundi	9
Sierra Leone	10
Rwanda	12
Uganda	12
Mali	13
Senegal	13
Zambia	14
Cameroon	19
Mozambique	19
Kenya	20
Angola	22
Madagascar	24
Ethiopia	25
Ghana	31
Congo DR	33
Tanzania	56
Nigeria	60

America	
Belize	1
Grenada	1
Guatemala	1
St. Lucia	1
Virgin Islands (brit.)	1
Tadzhikistan	1
Uzbekistan	1
West Bank & Gaza	1
Bhutan	2
Kyrgyztan	3
Nepal	3
Kazakhstan	5
Bangladesh	10
Thailand	16
Afghanistan	17
India	17
Pakistan	18
Cambodia	19
Myanmar	26
Laos	29
Vietnam	62

Pacific	
Fiji Islands	1
Samoa	1
Timor Leste	1
Australia*	2
Taiwan*	3
China*	6
Papua New Guinea	9
Indonesia	20
Philippines	29

Europe	
Belgium*	1
Italy*	1
Netherlands*	1
Norway*	1
Spain*	1
Switzerland*	2
Great Britain*	3
Germany*	7
Russia*	9

471	234	62	70	26	863
------------	------------	-----------	-----------	-----------	------------



1
2-3
4-9
10-19
≥ 20

The GPHF-Minilab™

A mini-laboratory developed by the Global Pharma Health Fund (GPHF) to boost the medicines testing capacity at healthcare providers in developing countries. Focus on priority essential medicines, for example anti-infectives. Non-sophisticated, affordable and fit for use in the field. Supplied more than 850 times to 98 countries already. Minilabs save lives. For more, go to www.gphf.org.



A charitable organisation voluntarily supported by Merck KGaA Darmstadt (Germany)

* For training and demonstration purposes only | Latest update February 2020